Research of CD200 as a new target therapy for colorectal liver metastases

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18129
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Nara Medical University
• Principal Investigator: Yasuko Matsuo 奈良県立医科大学, 医学部附属病院, 研究員 (10812315)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 大腸癌肝転移 / CD200 / 免疫療法

Outline of Final Research Achievements

The aim of this study was to evaluate the role of CD200, a potent immunosuppressive
molecule, in colorectal liver metastases (CRLM). The result showed that the overall survival of patients in the high-CD200 group was significantly worse than that in the low-CD200 group (p=0.009). Multivariate analysis showed that the high-CD200 expression was one of the independent prognostic factors in CRLM. Furthermore, tumor-infiltrating lymphocytes in CRLM were significantly higher in the low-CD200 group than in the high-CD200 group. CD200 may play a critical role in tumor immunity in CRLM, and can therefore be used as a potential therapeutic target in CRLM.

Free Research Field

消化器外科学

Academic Significance and Societal Importance of the Research Achievements

進行大腸癌は経過中に50-80%に肝転移を認め，肝転移の制御が大腸癌の予後改善には必須である．化学療法の進歩により予後は向上しているが，切除したとしても治癒に至る例は30%程度であり，新規治療法が望まれる．近年免疫チェックポイント阻害剤が新たな癌治療薬として効果を示している．CD200も免疫チェックポイント分子であるが，本研究において大腸癌肝転移におけるCD200発現が腫瘍免疫を介した新たな治療ターゲットとなり得る可能性が示唆された．この結果はこれまでに報告がなく，非常に意義のある研究と思われる．